Homepage Top Section2

Owned by Ampersand Capital Partners, Brammer Bio is engaged in the clinical and commercial supply of vectors for in vivo gene therapy and ex vivo gene-modified cell therapy.

Pfizer has paid around €45m ($51m) to purchase a 15% equity interest in Vivet Therapeutics, and will pay up to €560m that includes option exercise payment and certain

The public-private partnership between Evotec and GARDP will strive to address the increasing threat of antimicrobial resistance (AMR). It will combine GARDP’s clinical expertise and Evotec’s drug discovery

Tecentriq monoclonal antibody has been approved in combination with carboplatin and etoposide as a first-line treatment for adults with ES-SCLC. The approval was based on data from the

Based in Tokyo, Ayumi is engaged in the manufacturing and marketing of various drug products for anti-rheumatism and orthopedic pain management. Citing a person familiar with the matter,

Esperion said that bempedoic acid is under development as a complementary, cost-effective, once-daily and oral therapy to treat patients with elevated LDL-C. The company has submitted new drug

Upon completion of the transaction, Biogen Hillerød will become the fourth biopharmaceutical contract development and manufacturing site of Fujifilm. The large-scale biologics manufacturing facility is installed with 6

Trazimera has been approved to treat human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Pfizer Oncology global president

The committee concluded that Blincyto holds capacity to offer significant clinical benefits, while addition data on cost-effectiveness is required to evaluate its credibility for NHS funding. NICE has